Healthcare Services

A key trend shaping the Hepatorenal Syndrome Market involves the Innovative Therapies Target Liver And Kidney Dysfunction For Better Outcomes

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Hepatorenal Syndrome Market At The End Of The 2026–2030 Forecast Period?

The hepatorenal syndrome market has experienced substantial expansion recently. It is projected to increase from $1.37 billion in 2025 to $1.46 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.1%. This historical growth can be attributed to factors including the rising prevalence of chronic liver disease, an increasing incidence of cirrhosis-related complications, the expansion of intensive care unit infrastructure, enhanced clinical awareness of HRS diagnosis, and the availability of vasoconstrictor-based therapies.

The market for hepatorenal syndrome is projected to experience substantial growth over the coming years, reaching $1.91 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. This expansion during the forecast period is propelled by factors such as a rise in liver transplant procedures, a heightened emphasis on the early detection of HRS, the broader availability of advanced renal support therapies, an increasing embrace of precision medicine approaches, and greater investment in clinical research focused on hepatology. Key trends anticipated during this period encompass the increased adoption of targeted vasoconstrictor therapies, the expanded utilization of early diagnostic biomarkers, a growing emphasis on multidisciplinary critical care management, the development of albumin-based combination treatments, and improved monitoring of renal function in individuals with liver disease.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22001&type=smp

Which Market Drivers Are Supporting The Expansion Of The Hepatorenal Syndrome Market?

The growing occurrence of liver diseases is anticipated to fuel the expansion of the hepatorenal syndrome market. Liver diseases encompass conditions that impair liver function, such as hepatitis, cirrhosis, fatty liver, liver cancer, genetic disorders, and autoimmune conditions. Factors contributing to the rise in liver diseases include obesity, diabetes, alcohol consumption, viral infections, poor dietary habits, and exposure to toxins. The increasing prevalence of these diseases, particularly cirrhosis and acute liver failure, elevates the risk of hepatorenal syndrome (HRS) by inducing severe hemodynamic and kidney dysfunction through progressive liver damage. For example, in April 2024, the Office for Health Improvement & Disparities (OHID), a UK government department, reported that UK hospital admissions for liver disease climbed to 155.2 per 100,000 in 2023, an increase from 150.6 per 100,000 in 2022. Consequently, the rising prevalence of liver diseases is a key driver for the growth of the hepatorenal syndrome market. Increased investments in research and development are projected to stimulate the growth of the hepatorenal syndrome market. Research and development investments denote funds allocated for innovation, product enhancement, and the creation of new technologies. This upsurge in R&D funding is propelled by technological advancements, market competition, evolving healthcare needs, and the demand for innovative solutions. Such investments in hepatorenal syndrome drive progress in developing novel therapies, diagnostic tools, and treatment approaches, thereby enhancing patient outcomes and survival rates. For instance, in 2023, the Office for National Statistics, a UK-based government agency, stated that the UK government’s net expenditure on research and development (R&D) rose to £17.4 ($22.1 billion) billion in 2023, marking an 8.2% increase from £16.1 billion ($20.45 billion) in 2022. Thus, the growing investment in research and development is contributing significantly to the expansion of the hepatorenal syndrome market.

What Segment Types Make Up The Hepatorenal Syndrome Market?

The hepatorenal syndrome market covered in this report is segmented –

1) By Type: Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome, Other Types

2) By Treatment: Liver Transplantation, Terlipressin Infusion, Albumin Infusion, Hemodialysis, Vasoconstrictors

3) By Diagnosis: Liver Function Tests, Urinalysis And Urine Electrolytes, Other Diagnoses

4) By End Users: Hospitals, Specialty Clinics

Subsegments:

1) By Type 1 Hepatorenal Syndrome: Acute Kidney Injury-Associated HRS, Rapidly Progressive Renal Failure

2) By Type 2 Hepatorenal Syndrome: Chronic Kidney Dysfunction-Associated HRS, Slowly Progressive Renal Failure

3) By Other Types: HRS With Cirrhosis, HRS With Acute Liver Failure, HRS With Alcoholic Hepatitis

How Are Trends Shaping The Direction Of The Hepatorenal Syndrome Market?

Leading companies within the hepatorenal syndrome market are concentrating on developing innovative devices, such as cytopheretic devices, with the goal of improving patient outcomes by reducing inflammation, stabilizing renal function, and enhancing overall treatment effectiveness for Hepatorenal Syndrome (HRS). The cytopheretic device (Cytosorb) represents an extracorporeal blood purification therapy specifically designed to lessen systemic inflammation and immune activation in critically ill patients, including those afflicted with Hepatorenal Syndrome (HRS). For instance, in October 2023, SeaStar Medical Holding Corporation, a US-based medical device company, secured FDA approval for its Selective Cytopheretic Device (SCD) for the management of hepatorenal syndrome (HRS). This sophisticated, cell-directed therapy addresses hyperinflammation, a significant factor contributing to kidney dysfunction in individuals with acute-on-chronic liver failure. Through the application of immunomodulation, SCD helps regulate abnormal immune responses, potentially facilitating kidney recovery and enhancing patients’ qualifications for life-saving liver transplants. Its proven efficacy in boosting solid organ function has been observed in preclinical and clinical studies across conditions like sepsis, acute kidney injury (AKI), and cardiorenal syndrome.

Who Are The Key Players Driving Competition In The Hepatorenal Syndrome Market?

Major companies operating in the hepatorenal syndrome market are Eli Lilly and Company, Baxter International Inc., Mallinckrodt Pharmaceuticals, Ferring Pharmaceuticals Ltd, La Jolla Pharmaceutical Company, Teva Pharmaceutical Industries Ltd, Cumberland Pharmaceuticals Inc., Innoviva Specialty Therapeutics Inc, BioVie Inc., SeaStar Medical, Otsuka Pharmaceutical Co. Ltd, Pfizer Inc., AbbVie Inc., Bristol Myers Squibb, Novartis AG, Sanofi, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Bayer AG, AstraZeneca

Read the full hepatorenal syndrome market report here:

https://www.thebusinessresearchcompany.com/report/hepatorenal-syndrome-global-market-report

How Is The Hepatorenal Syndrome Market Distributed Across Key Geographic Regions?

North America was the largest region in the hepatorenal syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatorenal syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Hepatorenal Syndrome Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22001&type=smp

Browse Through More Reports Similar to the Global Hepatorenal Syndrome Market 2026, By The Business Research Company

Hepatic Encephalopathy Global Market Report

https://www.thebusinessresearchcompany.com/report/hepatic-encephalopathy-global-market-report

Dumping Syndrome Global Market Report

https://www.thebusinessresearchcompany.com/report/dumping-syndrome-global-market-report

Heparin Global Market Report

https://www.thebusinessresearchcompany.com/report/heparin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795